Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia. (21st October 2012)

• Record Type: Journal Article
• Authors: Vandeix, E.; Favard, F.; Pichon, N.; Delage-Corre, M.; Melloni, B.; Clavel, M.
• Other Names: Hillerdal G. Academic Editor.; Takao M. Academic Editor.; Watanabe K. Academic Editor.
• Is Part Of: Case reports in pulmonology. Volume 2012(2012)
• Publication Date: 2012-10-21
• Subjects: Lungs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory infections -- Periodicals; Lung Diseases; Respiratory Tract Diseases; Respiratory Tract Infections; Lungs -- Diseases; Respiratory infections; Respiratory organs -- Diseases; Periodicals; Case Reports; Electronic journals; Periodicals; 616.2
• DOI: 10.1155/2012/430141
• Languages: English
• ISSNs: 2090-6846

Abstract

Abstract : Introduction . Bortezomib is a proteasome inhibitor indicated for the treatment of multiple myeloma patients. The most frequent side effects are gastrointestinal and neurological. Serious pulmonary complications have been described rarely. Observation . This case involves a 74-year-old man suffering from IgG Kappa myeloma treated with bortezomib, melphalan, and dexamethasone. After administering chemotherapy, the patient developed an acute respiratory distress syndrome (ARDS). A surgical pulmonary biopsy proved the existence of bronchiolitis obliterans organizing pneumonia (BOOP) lesions. Systemic corticotherapy led to a rapid improvement in the patient's condition. Conclusion . This is the first reported histologically confirmed case of bortezomid-induced BOOP. Faced with severe respiratory symptoms in the absence of other etiologies, complications due to bortezomid treatment should be evoked and corticotherapy considered.